Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	25D0316753	06/23/2022
Name of Provider or Supplier	**Street Address, City, State**	
Delta Health System - The Medical Center	1400 East Union St - Laboratory, Greenville, MS	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5507	BACTERIOLOGY CFR(s): 493.1261(b)(c) (b) For antimicrobial susceptibility tests, the laboratory must check each batch of media and each lot number and shipment of antimicrobial agent(s) before, or concurrent with, initial use, using approved control organisms. (b)(1) Each day tests are performed, the laboratory must use the appropriate control organism(s) to check the procedure. (b)(2) The laboratory's zone sizes or minimum inhibitory concentration for control organisms must be within established limits before reporting patient results. (c) The laboratory must document all control procedures performed, as specified in this section. This STANDARD is not met as evidenced by: Based on review of quality control (QC) records for the BD Phoenix M50 antimicrobial susceptibility system since 3-5-21, lack of documentation of an Individualized Quality Control Plan (IQCP), and confirmation by the technical supervisor on 6-21-22, the laboratory failed to either perform quality control testing with appropriate control organisms each day of susceptibility testing or develop an IQCP. The technical supervisor confirmed an IQCP was not developed for susceptibility testing performed on the BD Phoenix M50 antimicrobial susceptibility system. Findings include: Review of QC records for the BD Phoenix M50 antimicrobial susceptibility system since 3-5-21 revealed quality control for susceptibility testing was performed weekly with the appropriate control organisms. There was no documentation of establishment of an IQCP, required after 1-1-16 if quality control is not included each day of patient susceptibility testing. The technical supervisor confirmed an IQCP was not developed for susceptibility testing performed on the BD Phoenix M50 antimicrobial susceptibility system.
D6053	TECHNICAL CONSULTANT RESPONSIBILITIES CFR(s): 493.1413(b)(9)

	The technical consultant is responsible for evaluating and documenting the performance of individuals responsible for moderate complexity testing at least semiannually during the first year the individual tests patient specimens. This STANDARD is not met as evidenced by: Based on review of testing personnel records from 2/21/2021 through 6/23/22, the Centers for Medicare and Medicaid Services (CMS) 209 personnel form and interview with the technical consultant (TC), the TC failed to evaluate and document the performance of TP #8 in the Cath Lab department and TP # 4, TP #10 and #12 in the OB department at least semiannually during the first year of employment. Findings include: 1. Review of the Cath Lab personnel records indicated that TP #8 had an initial training performed in December 2020 and began testing on patients. An annual evaluation was performed on 12/22/2021. There was no six month evaluation /competency available for review on the day of survey which is required in the first year of testing. 2. Review of the OB nursing department personnel records revealed: a. TP #4 had initial training on 11/11/2021. There was no documented 6 month competency evaluation available for review on 6/23/2022. b. TP#10 had initial training on 11/10/2021. There was no documented 6 month competency evaluation available for review on 6/23/2022. c. TP#12 had initial training on 11/12/2021. There was no documented 6 month competency evaluation available for review on 6/23 /2022. 3. The technical consultant for the Cath Lab and OB nursing departments confirmed in an interview at 3:00 p.m. on 6/23/22 that there was no 6 month evaluation/competency performed on TP #8 in the Cath lab and TP#4, TP#10 or TP#12 in the OB Nursing department.